CA2462272A1 - Methods for treating dry eye by a combination of an antiinflammatory steroid and a muc-1 secretagogue - Google Patents

Methods for treating dry eye by a combination of an antiinflammatory steroid and a muc-1 secretagogue Download PDF

Info

Publication number
CA2462272A1
CA2462272A1 CA002462272A CA2462272A CA2462272A1 CA 2462272 A1 CA2462272 A1 CA 2462272A1 CA 002462272 A CA002462272 A CA 002462272A CA 2462272 A CA2462272 A CA 2462272A CA 2462272 A1 CA2462272 A1 CA 2462272A1
Authority
CA
Canada
Prior art keywords
free
functionally modified
group
alkyl
ident
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002462272A
Other languages
French (fr)
Inventor
Daniel A. Gamache
John M. Yanni
Barry F. Van Duzee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2462272A1 publication Critical patent/CA2462272A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Methods of treating dry eye by administering fixed combinations of MUC-1 secretagogues, such as HETE derivatives, and anti-inflammatory steroids are disclosed.

Description

METHODS FOR TREATING DRY EYE BY A COMBINATION OF AN ANTIINFLAMMATORY STEROID

The present invention is directed to methods for treating dry eye. The methods comprise administering compositions containing combinations of mucin-1 secretagogues and anti-inflammatory steroids.
Background of the Invention 1o Dry eye, also known generically as keratoconjunctivitis sicca, is a common ophthalmological disorder affecting millions of Americans each year.
The condition is particularly widespread among post-menopausal women due to hormonal changes following the cessation of fertility. Dry eye may afflict an individual with varying severity. In mild cases, a patient may experience 5 burning, a feeling of dryness, and persistent irritation such as is often caused by small bodies lodging between the eye lid and the eye surface. In severe cases, vision may be substantially impaired. Other diseases, such as~
Sjogren's disease and cicatricial pemphigoid manifest dry eye complications.
::
2o Although it appears that dry eye may result from a number of unrelated pathogenic causes, all presentations of the complication share a common effect, that is the breakdown of the pre-ocular tear film, which results in dehydration of the exposed outer surface and many of the symptoms outlined above (Lamp, Report of the National Eye Institutellndustry Workshop on z5 Clinical Trials in Dry Eyes, The CLAD Journal, volume 21, number 4, pages 221-231 (1995)).
Practitioners have taken several approaches to the treatment of dry eye. One common approach has been to supplement and stabilize the ocular 3o tear film using so-called artificial tears instilled throughout the day.
Other approaches include the use of ocular inserts that provide a tear substitute or stimulation of endogenous tear production.

Examples of the tear substitution approach include the use of buffered, isotonic saline solutions, aqueous solutions containing water soluble polymers that render the solutions more viscous and thus less easily shed by the eye.
Tear reconstitution is also attempted by providing one or more components of the tear film such as phospholipids and oils. Phospholipid compositions have been shown to be useful in treating dry eye; see, e.g., McCulley and Shine, Tear film structure and dry eye, Contactologia, volume 20(4), pages 145-49 (1998); and Shine and McCulley, ICeratoconjunctivitis sicca associated with meibomian secretion polar lipid abnormality, Archives of Ophthalmoloay, volume 116(7), pages 849-52 (1998). Examples of phospholipid compositions for the treatment of dry eye are disclosed in U.S. Patent Nos.
4,131,651 (Shah et al.), 4,370,325 (Packman), 4,409,205 (Shively), 4,744,980 and 4,883,658 (Holly), 4,914,088 (Glonek), 5,075,104 (Gressel et al.), 5,278,151 (Korb et al.), 5,294,607 (Glonek et al.), 5,371,108 (Korb et al.) and 5,578,586 (Glonek et al.). U.S. Patent No. 5,174,988 (Mautone et al.) discloses phospholipid drug delivery systems involving phospholipids, propellants and an active substance.
Another approach involves the provision of lubricating substances in 20 lieu of artificial tears. For example, U.S. Patent No. 4,818,537 (Guo) discloses the use of a lubricating, liposome-based composition, and U.S.
Patent No. 5,800,807 (Hu et al.) discloses compositions containing glycerin and propylene glycol for treating dry eye.
25 Although these approaches have met with some success, problems in the treatment of dry eye nevertheless remain. The use of tear substitutes, while temporarily effective, generally requires repeated application over the course of a patient's waking hours. It is not uncommon for a patient to have to apply artificial tear solution ten to twenty times over the course of the day.
3o Such an undertaking is not only cumbersome and time consuming, but is also potentially very expensive. Transient symptoms of dry eye associated with refractive surgery have been reported to last in some cases from six weeks to six months or more following surgery.
Aside from efforts directed primarily to the alleviation of symptoms associated with dry eye, methods and compositions directed to treatment of the dry eye condition have also been pursued. For example, U.S. Patent No.
5,041,434 (Lubkin) discloses the use of sex steroids, such as conjugated estrogens, to treat dry eye conditions in post-menopausal women; U.S.
Patent No. 5,290,572 (MacKeen) discloses the use of finely divided calcium ion compositions to stimulate pre-ocular tear film production; and U.S. Patent No. 4,966,773 (Gressel et al.) discloses the use of microfine particles of one or more retinoids for ocular tissue normalization.
Some recent literature reports suggest that patients suffering from dry eye syndrome disproportionately exhibit the hallmarks of excessive inflammation in relevant ocular tissues, such as the lacrimal and meibomian 5 glands. The use of steroids and cytokine release inhibitors to treat dry eye patients has been disclosed: U.S. Patent No: 5,958,912; Pflugfelder, et. al.
U.S. Patent No. 6,153,607; and Yanni, J.M.; et. al. WO 0003705 A1.
Additionally, cyclosporine A [Tauber, J. Adv. Exp. Med. Biol. 1998 438 (Lacrimal Gland, Tear Film, and Dry Eye Syndromes 2), 969] has been o disclosed for treating dry eye.
Corticosteroids, such as prednisolone and loteprednol, reduce inflammation but cannot be used for prolonged therapy in dry eye, patients due to the propensity of steroids to elicit ocular side effects. Steroid-related z5 complications including increased intraocular pressure and cataract formation have been observed in dry eye patients treated with corticosteroids after several months of therapy. See Marsh, et al., Ophthalmoloay, 106(4}: 811-816 (1999). Marsh, et al, conclude: "Because of the chronic nature of [dry eye] disease and the likelihood of patients developing steroid-related 3o complications with their long-term use, topical nonpreserved methylprednisolone therapy appears to be most appropriate for short-term 'pulse' treatment of exacerbations of keratoconjunctivits sicca." Id. at 811.

Agents claimed for increasing ocular mucin and/or tear production include vasoactive intestinal polypeptide (Dartt et. al., Vasoactive intestinal peptide-stimulated glycocongjugate secretion from conjunctiva) goblet cells.
Experimental Eye Research, volume 63, pages 27-34, (1996)), gefarnate (Nakmura et. al., Gefarnate stimulates secretion of mucin-like glycoproteins by corneal epithelium in vitro and protects corneal epithelium from dessication in vivo, Experimental Eye Research, volume 65, pages 569-574 (1997)), liposomes (U.S. Patent No. 4,818,537), androgens (U.S. Patent No.
5,620,921), melanocycte stimulating hormones (U.S. Patent No. 4,868,154), o phosphodiesterase inhibitors (U.S. Patent No. 4,753,945), and retinoids (U.S.
Patent No. 5,455,265).
U.S. Patent No. 5,696,166 discloses the use of certain HETE
derivatives, including 15-HETE, for treating dry eye and other disorders 5 requiring the wetting of the eye. According to the '166 patent, the HETE
derivatives stimulate mucin production and/or secretion in the conjunctiva) epithelium and goblet cells. Preferably, 'the HETE derivatives are. topically ..administered to the eye. 15-HETE has been shown to increase the secretion . of rnucin-1 (MUC-1 ) from human conjunctiva) epithelial cells.

Summary of the Invention The present invention is directed to combinations of MUC-1 secretagogues and anti-inflammatory steroids for use in treating dry eye and 5 other disorders requiring the wetting of the eye (disorders that require restoring an intact ocular surface and normal tear function), including symptoms of dry eye associated with refractive surgery such as LASIK
surgery. The compositions are preferably adrrtinistered topically to the eye.
3o The methods of the present invention provide the advantages of simultaneously treating two aspects of dry eye: stimulating the secretion of an essential tear component (MUC-1 ) and treating the inflammatory component of dry eye. The methods of the present invention are superior to methods that administer either MUC-1 secretagogues or steroids alone. The combination of the present invention consists of a MUC-1 secretagogue, which provides protection of corneal and conjunctival epithelial cells from dessication, with concomitant treatment of ocular surface inflammation by a steroid. The combination permits the use of lower concentrations of drugs, a more rapid onset of action, and a greater duration of effect than either therapy alone.
Among other factors, the present invention is based on the finding that o epithelial cells produce MUC-1 and this mucin is bound to the surface of the epithelial cells where it forms the basal level of tears. The aqueous tear components are held on the eye and spread over the surface of the eye by interaction with this basal MUC-1 layer of mucin attached to the ocular surface epithelial cells. MUC-1 is the only mucin subtype produced by ~5 epithelial cells of both the cornea and conjunctiva. MUC-1 is not secreted by goblet cells. Goblet cells often decrease in number and function. in dry eye patients.
Detailed Description of the Invention Zo The present invention is directed to methods of treating dry eye and other disorders requiring the wetting of the eye by administering compositions comprising a MUC-1 secretagogue and an anti-inflammatory steroid.
As used herein, "MUC-1 secretagogue" means a compound that elicits the production or secretion of MUC-1 by epithelial cells. MUC-1 secretagogues may also elicit production or secretion of other species of mucin, but selectively elicit the production or secretion of MUC-1. Preferred 3o MUC-1 secretagogues are HETE derivatives. "HETE derivative" means a compound selected from the group consisting of the compounds of formulas II-XIV below and pharmaceutically acceptable salts, esters and amides thereof. The most preferred MUC-1 secretagogue is 15(S)-HETE.
C02H / Y~C02H CO H
Y~ ~ Y
II III IV
wherein:
Y is C=O (i.e., a carbonyl), or CH(OH) in either configuration, wherein the hydroxy group can be free or functionally modified;
~a V:
Z Z~ 5 5 ~~K T~C02H

B5 D'E~G Y~/~/
V
wherein:
Z and Z~ are H, or ZZ~ is CH2;
B5-D5, E5-G5 and T5-K5 are the same or different and are CH2CH2, CH=CH, or C---C;
Y5 is C=O (i.e., a carbonyl), or CH(OH) in either configuration, wherein the hydroxy group can be free or functionally modified;
2o VI:
X6~C02H
~ 6 "-K6 T~ L6-Y6'~/~/
VI
wherein:
X6 is CHZCH2CH=CH, CH2CH2C--_C, CH2CH2CH2CH2, CH2CH=CHCH2, CH2C--__CCH2, CH=CHCH2CH2, C---CCH2CH2, CH2CH=C=CH, or CH=C=CHCH2;
K6-T6-L6 is CH2CH2CH2, CH2CH=CH, CH2C--_C, CH=CHCH2, C---CCH2, or CH=C=CH;
Y6 is C=O (i.e., a carbonyl), or CH(OH) in either configuration, wherein the hydroxy group can be free or functionally modified;
VII:
~ X~~C02H
D~ E~~~T~ Y''~/~/
VII
wherein:
X' is CH2CH2CH2, CH2CH=CH, CH2C=C, CH=CHCH2, C---CCH2, or CH=C=CH;
D'-E' and G'-T' are the same or different and are CH2CH2, CH=CH, or C---C;
Zo Y' is C=O (i.e., a carbonyl), or CH(OH) in either configuration, wherein the hydroxy group can be free or functionally modified;
VIII:
s X$~COZH
A ~B$ Y$CSH~~-n Zs VIII
wherein:
X$ is C2-C5 alkyl, alkynyl, or alkenyl, or a C3-C5 allenyl group;
J$ is H, free or functionally modified hydroxy group, halo, trihalomethyl, free or functionally modified amino group, free or functionally modified thiol group, C(O)R8, or alkyl;
R$ is H, OH, alkyl, alkoxy, amino, alkylamino, or alkoxyamino;
o A$ is direct bond or C~_3 alkyl;
B$ is CH2CH2, cis- or trans-CH=CH, or C---C;
Y$ is C=O (i.e., a carbonyl), or CH(OH) in either configuration, wherein the hydroxy group can be free or functionally modified;
IX:
9 p9 (CH2)p C02H
G, -Y 9 s T ~(CH2)n Z
IX
20 wherein:
E9-D9 is CH2CH2CH2 or cis-CH2CH=CH; or E9 is trans-CH=CH and D9 is CH(OH) in either configuration, wherein the OH is free or functionally modified; or E9 is CH2CH2 and D9 is a direct bond;
25 p is 1 or 3 when E9-D9 is CH2CH2CH2 or cis-CH2CH=CH, or when E9 is trans-CH=CH and D9 is CH(OH) in either configuration, wherein the OH is free or functionally modified; or p is 0 when E9 is CH2CH2 and D9 is a direct bond;
3o G9-T9 is CH2CH2, CH(SR)CHa, or trans-CH=CH;
s SR comprises a.free or functionally modified thiol group;
n is 0, 2, or 4;
Z9 is CH3, C02R9, CONR2R3, or CH20R4;
R9 is H or C02R9 forms a pharmaceutically acceptable salt or a pharmaceutically acceptable ester;
o NR2R3 forms a free or functionally modified amino group;
OR4 forms a free or functionally modified hydroxy group;
Y9 is C=O (i.e., a carbonyl), or CH(OH) in either configuration, wherein ,5 the hydroxy group can be free or functionally modified;
X:

D-E~ ~T-Y~/~/
X
z0 wherein:
IC1° is C2_C~ alkyl, alkenyl, or alkynyl, or a C3-C7 allenyl group;
A1° and X1° are the same or different and are a direct bond, CH2, NR11, 25 O, or S, with the proviso that at least one of A and X is NR11, O, or S;
B1° are both H, or B1°B1° together forms a double bonded O, S, or NR12, with the proviso that g~oBlo is a double bonded O, S, or NR12 when A1° and X1° are the same or different and are NR11, O, or S;

NR11 and NR12 are the same or different and comprise a free or functionally modified amino group;
D1o-E1o and G1°-T1° are the same or different and are CH2CHz, CH=CH, or C---C;
~0 XI:
Y1° is C=O (i.e., a carbonyl), or CH(OH) in either configuration, wherein the hydroxy group can be free or functionally modified;
~B 1~ A1~~CO2 H
X11 D11Y11 F I' XI
wherein:
A11, B11, C11 and D11 are the same or different and are C1-C5 alkyl, alkenyl, or alkynyl, or a C3-C5 allenyl group;
Y11 IS C=O (i.e., a carbonyl), or CH(OH) in either configuration, wherein the hydroxy group can be free or functionally modified;
B 1~A~C02H

C-D X, 1~
Y
wherein:
XII
A12, 812 C12 and D12 are the same or different and are C1-C5 alkyl, alkenyl, or alkynyl, or a C3-C5 allenyl group;

Y12 is CH(OH) or CCH3(OH) in either configuration, wherein the hydroxy group can be free or functionally modified, and X12 is CH2, CH(CH3) or C(CH3)2; or Y12 is CH2, CH(CH3) or C(CH3)2, and X12 is CH(OH) or CCH3(OH) in either configuration, wherein the hydroxy group can be free or functionally modified;
XIII:

B~A~COZH

C-D-E~X~Y 13 x111 wherein:
A13~ 813 C13 and D13 are the same or different and are C1-C5 alkyl, C2-C5 alkenyl, C1-C5 cyclopropyl, C2-C5 alkynyl, or a C3-C5 allenyl group;
E13 is CH(OH), where the hydroxy group is free or functionally modified;
20 X13 is (CH2)m or (CH2)m0, wherein m is 1-6, and Y13 is a phenyl ring optionally substituted with alkyl, halo, trihalomethyl, acyl, or a free or functionally modified hydroxy, amino, or thiol group; or X13-Y13 is (CH2)pY2l; wherein p is 0-6; and Y21 - \ ~ ~ Z13 or Wla~ ~ X13 wherein:

W13 is CH2, O, S(O)q, NR18, CH2CH2, CH=CH, CH20, CH2S(O)q, CH=N, or CH2NR18; wherein q is 0-2, and R1$ is H, alkyl, or acyl;
Z13 is H, alkyl, acyl, halo, trihalomethyl, or a free or functionally modified amino, thiol, or hydroxy group; and -- is a single or double bond;
0 or X13-Y13 is cyclohexyl; and XIV:

XIV
wherein:
OR14 and OR15 are the same or different and comprise a free or functionally modified hydroxy group;
G14~ T14 and Z14 are the same or different and are CH2CH2, cis- or trans-CH=CH or C---C;
2o is C--__C or cis-CH=CH;
one of A14, g14 is H or CH3, and the other is a free or functionally modified hydroxy group, or A14-B14 comprises a double bonded oxygen as a carbonyl, 25 or A14-B14 IS OCH2CH20;
X14 IS CR16R17(CH2)q Or CR16R17(CH2)qO, Wlth q IS 0-6;

R16 and R1' are the same or different and are H or CH3;
Y 14 is CH3, or a phenyl ring optionally substituted with alkyl, halo, trihalomethyl, acyl, or a free or functionally modified hydroxy, thiol, or amino group;
Or X14-Y14 Is (CH2)pY20, p is ~-6, J14~r W14 ~ ~ J14 '' \ /
S
~~~nwwvv~
wherein:
W14 is CH2, O, S(O)n,, NR21, CH2CH2, CH=CH, CH20, CH2S(O),r, CH=N, or CH2NR21;

m is 0-2;
NR21 is NH or a functionally modified amino group;
Zo J14 is H, alkyl, acyl, halo, trihalomethyl, or a free or functionalized hydroxy, thiol, or amino group; and -- is a single or double bond;
z5 or X14-Y14 Is cyclohexyl.
Included within the scope of the present invention are the individual enantiomers of the compounds of formulas II - XIV, as well as their racemic and non-racemic mixtures. The individual enantiomers can be enantioselectively synthesized from the appropriate enantiomerically pure or enriched starting material by means such as those described below.
Alternatively, they may be enantioselectively synthesized from racemic/non-racemic or achiral starting materials. (Asymmetric Synthesis; J. D. Morrison and J. W. Scott, Eds.; Academic Press Publishers: New York, 1983-1985, volumes 1-5; Principles of Asymmetric Synthesis; R.E. Gawley and J. Aube, Eds.; Elsevier Publishers: Amsterdam, 1996). They may also be isolated from racemic and non-racemic mixtures by a number of known methods, e.g.
by purification of a sample by chiral HPLC (A Practical Guide to Chiral 0 Separations by HPLC; G. Subramanian, Ed.; VCH Publishers: New York, 1994; Chiral Separations by HPLC; A.M. Krstulovic, Ed.; Ellis Horwood Ltd.
Publishers, 1989), or by enantioselective hydrolysis of a carboxylic acid ester sample by an enzyme (Ohno, M.; Otsuka, M. Organic Reactions volume 37, page 1 (1989)). Those skilled in the art will appreciate that racemic and non-racemic mixtures may be obtained by several means, including without limitation, nonenantioselective synthesis, partial resolution, or even mixing samples.having different enantiomeric ratios. Also included within the, scope of the present invention are the individual isomers substantially free of their respective enantiomers.
2o As used herein, wavy line attachments indicate that the configuration may be either alpha (a) or beta (a). Hatched lines indicate the a configuration. A solid triangular line indicates the ~ configuration.
25 The term "free hydroxy group" means an OH. The term "functionally modified hydroxy group" means an OH which has been functionalized to form:
an ether, in which an alkyl, aryl, cycloalkyl, heterocycloalkyl, alkenyl, cycloalkenyl, heterocycloalkenyl, alkynyl, or heteroaryl group is substituted for the hydrogen; an ester, in which an acyl group is substituted for the hydrogen;
30 a carbamate, in which an aminocarbonyl group is substituted for the hydrogen; or a carbonate, in which an aryloxy-, heteroaryloxy-, alkoxy-, cycloalkoxy-, heterocycloalkoxy-, alkenyloxy-, cycloalkenyloxy-, heterocycloalkenyloxy-, or alkynyloxy-carbonyl group is substituted for the hydrogen. Preferred moieties include OH, OCH2C(O)CH3,OCH2C(O)C2H5, OCH3, OCH2CH3, OC(O)CH3, and OC(O)C2H5.
The term "free amino group" means an NH2. The term "functionally modified amino group" means an NH2 which has been functionalized to form:
an aryloxy-, heteroaryloxy-, alkoxy-, cycloalkoxy-, heterocycloalkoxy-, alkenyl-, cycloalkenyl-, heterocycloalkenyl-, alkynyl-, or hydroxy-amino group, wherein the appropriate group is substituted for one of the hydrogens; an aryl-, heteroaryl-, alkyl-, cycloalkyl-, heterocycloalkyl-, alkenyl-, cycloalkenyl-, 0 heterocycloalkenyl-, or alkynyl-amino group, wherein the appropriate group is substituted for one or both of the hydrogens; an amide, in which an acyl group is substituted for one of the hydrogens; a carbamate, in which an aryloxy-, heteroaryloxy-, alkoxy-, cycloalkoxy-, heterocycloalkoxy-, alkenyl-, cycloalkenyl-, heterocycloalkenyl-, or alkynyl-carbonyl group is substituted for one of the hydrogens; or a urea, in which an aminocarbonyl group is substituted for one of the hydrogens. Combinations of these substitution patterns, for example an ~NHa in which one of the hydrogens is replaced by an a;alkyl -group and the other. hydrogen is replaced by an' alkoxycarbonyl group, also fall under the definition of a functionally modified amino group and are ZO included within the scope of the present invention. Preferred moieties include NH2, NHCH3, NHC2H5, N(CH3)2, NHC(O)CH3, NHOH, and NH(OCH3).
The term "free thiol group" means an SH. The term "functionally modified thiol group" means an SH which has been functionalized to form: a z5 thioether, where an alkyl, aryl, cycloalkyl, heterocycloalkyl, alkenyl, cycloalkenyl, heterocycloalkenyl, alkynyl, or heteroaryl group is substituted for the hydrogen; or a thioester, in which an acyl group is substituted for the hydrogen. Preferred moieties include SH, SC(O)CH3, SCH3, SC2H5, SCH2C(O)C2H5, and SCH2C(O)CH3.
The term "acyl" represents a group that is linked by a carbon atom that has a double bond to an oxygen atom and a single bond to another carbon atom.

The term "alkyl" includes straight or branched chain aliphatic hydrocarbon groups that are saturated and have 1 to 8 carbon atoms. The alkyl groups may be interrupted by one or more heteroatoms, such as oxygen, nitrogen, or sulfur, and may be substituted with other groups, such as halogen, hydroxyl, aryl, cycloalkyl, aryloxy, or alkoxy. Preferred straight or branched alkyl groups include methyl, ethyl, propyl, isopropyl, butyl and t butyl.
The term "cycloalkyl" includes straight or branched chain, saturated or unsaturated aliphatic hydrocarbon groups which connect to form one or more rings, which can be fused or isolated. The rings may be substituted with other groups, such as halogen, hydroxyl, aryl, aryloxy, alkoxy, or lower alkyl..
Preferred cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl and ~5 cyclohexyl.
The term "C~ - C5 cyclopropyl" means an alkyl chain of 1 to 5 carbon atoms containing a cyclopropyl group v~iherein the cyclopropyl group: may start, be contained in or terminate the alkyl chain.
zo The term "heterocycloalkyl" refers to cycloalkyl rings that contain at least one heteroatom such as O, S, or. N in the ring, and can be fused or isolated. The rings may be substituted with other groups, such as halogen, hydroxyl, aryl, aryloxy, alkoxy, or lower alkyl. Preferred heterocycloalkyl Z5 groups include pyrrolidinyl, tetrahydrofuranyl, piperazinyl, and tetrahydropyranyl.
The term "alkenyl" includes straight or branched chain hydrocarbon groups having 1 to 8 carbon atoms with at least one carbon-carbon double 3o bond, the chain being optionally interrupted by one or more heteroatoms.
The chain hydrogens may be substituted with other groups, such as halogen, Preferred straight or branched alkenyl groups include, allyl, 1-butenyl, 1-methyl-2-propenyl and 4-pentenyl.

The term "cycloalkenyl" includes straight or branched chain, saturated or unsaturated aliphatic hydrocarbon groups which connect to form one or more non-aromatic rings containing a carbon-carbon double bond, which can be fused or isolated. The rings may be substituted with other groups, such as halogen, hydroxyl, alkoxy, or lower alkyl. Preferred cycloalkenyl groups include cyclopentenyl and cyclohexenyl.
The term "heterocycloalkenyl" refers to cycloalkenyl rings which contain 0 one or more heteroatoms such as O, N, or S in the ring, and can be fused or isolated. The rings may be substituted with other groups, such as halogen, hydroxyl, aryl, aryloxy, alkoxy, or lower alkyl. Preferred heterocycloalkenyl groups include pyrrolidinyl, dihydropyranyl, and dihydrofuranyl. .
The term "carbonyl group" represents a carbon atom double bonded to an oxygen atom, wherein the carbon atom has two free valencies.
The term "aminocarbonyl" represents a free .or functionally modified ' . amino group bonded from its nitrogen atom to the carbon atom of a carbonyl zo group, the carbonyl group itself being bonded to another atom through its carbon atom.
The term "lower alkyl" represents alkyl groups containing one to six carbons (C~-Cg).

The term "halogen" represents fluoro, chloro, bromo, or iodo.
The term "aryl" refers to carbon-based rings which are aromatic. The rings may be isolated, such as phenyl, or fused, such as naphthyl. The ring 3o hydrogens may be substituted with other groups, such as lower alkyl, halogen, free or functionalized hydroxy, trihalomethyl, etc. Preferred aryl groups include phenyl, 3-(trifluoromethyl)phenyl, 3-chlorophenyl, and 4-fluorophenyl.

The term "heteroaryl" refers to aromatic hydrocarbon rings which contain at least one heteroatom such as O, S, or N in the ring. Heteroaryl rings may be isolated, with 5 to 6 ring atoms, or fused, with 8 to 10 atoms.
The heteroaryl rings) hydrogens or heteroatoms with open valency may be substituted with other groups, such as lower alkyl or halogen. Examples of heteroaryl groups include imidazole, pyridine, indole, quinoline, furan, thiophene, pyrrole, tetrahydroquinoline, dihydrobenzofuran, and dihydrobenzindole.
The terms "aryloxy", "heteroaryloxy", "alkoxy", "cycloalkoxy", "heterocycloalkoxy", "alkenyloxy", "cycloalkenyloxy", "heterocycloalkenyloxy", and "alkynyloxy" represent an aryl, heteroaryl, alkyl, cycloalkyl, heterocycloalkyl, alkenyl, cycloalkenyl, heterocycloalkenyl, or alkynyl group, 5 respectively, attached through an oxygen linkage.
The terms "alkoxycarbonyl", "aryloxycarbonyl", "heteroaryloxycarbonyl", "cycloalkoxycarbonyl", "heterocycloalkoxycarbonyl", : ~ "alkenyloxycarbonyl", "cycloalkenyloxycarbonyl",~ ."heterocycloalkenyloxycarbonyl", and "alkynyloxycarbonyl" represent an alkoxy, aryloxy, heteroaryloxy, cycloalkoxy, heterocycloalkoxy, alkenyloxy, cycloalkenyloxy, heterocycloalkenyloxy, or alkynyloxy group, respectively, bonded from its oxygen atom to the carbon of a carbonyl group, the carbonyl group itself being bonded to another atom through its carbon atom.
In addition to one or more MUC-1 secretagogues, the compositions administered according to the methods of the present invention comprise one or more anti-inflammatory steroids. Preferred anti-inflammatory steroids are those with a favorable safetyprofile due to propertiessuch as limited 3o distributionfrom ocular surfaceand/or rapid catabolismwithin the eye.

Examples of anti-inflammatorysteroids include, not limited but are to, rimexolone, loteprednol, medrysone and hydrocortisone.

According to the methods of the present invention, a composition comprising at least one MUC-1 secretagogue, at least one ocular surface-selective steroid and a pharmaceutically acceptable carrier for topical ophthalmic administration or implantation into the conjunctiva) sac or anterior chamber of~ the eye is administered to a mammal in need thereof. The compositions are formulated in accordance with methods known in the art for the particular route of administration desired.
Generally, compositions intended to be administered topically to the o eye in the form of eye drops or eye ointments will contain approximately 0.00001 to 0.1 % of MUC-1 secretagogue and 0.001 to 1 % of an anti inflammatory steroid. Preferably, the MUC-1 secretagogue is a HETE
derivative and the amount of HETE derivative is 0.00001 to 0.0001 %. The preferred amount of anti-inflammatory steroid is 0.01 to 0.2 The compositions administered according to the present invention may also include various other ingredients, including but not~limited to surfactants, tonicity agents, buffers; preservatives, .co-solvents and viscosity ~ building 2o agents.
Various tonicity agents may be employed to adjust the tonicity of the composition, preferably to that of natural tears for ophthalmic compositions.
For example, sodium chloride, potassium chloride, magnesium chloride, calcium chloride, dextrose and/or mannitol may be added to the composition to approximate physiological tonicity. Such an amount of tonicity agent will vary, depending on the particular agent to be added. In general, however, the compositions will have a tonicity agent in an amount sufficient to cause the final composition to have an ophthalmically acceptable osmolality (generally 3o about 150 - 450 mOsm, preferably 250 - 350 mOsm).
An appropriate buffer system (e.g., sodium phosphate, sodium acetate, sodium citrate, sodium borate or boric acid) may be added to the compositions to prevent pH drift under storage conditions. The particular concentration will vary, depending on the agent employed. Preferably, however, the buffer will be chosen to maintain a target pH within the range of pH 6-7.5.
Compositions formulated for the treatment of dry eye-type diseases and disorders may also comprise aqueous carriers designed to provide immediate, short-term relief of dry eye-type conditions. Such carriers can be formulated as a phospholipid carrier or an artificial tears carrier, or mixtures of o both. As used herein, "phospholipid carrier" and "artificial tears carrier"
refer to aqueous compositions which: (i) comprise one or more phospholipids (in the case of phospholipid carriers) or other compounds, which lubricate, "wet,"
approximate the consistency of endogenous tears, aid in natural tear build-up, or otherwise provide temporary relief of dry eye symptoms and conditions 5 upon ocular administration; and (ii) are safe. Examples or artificial tears compositions useful as artificial tears carriers include, but are not limited to, commercial products, such as Tears Naturale~, Tears Naturale II~, Tears _~ Naturale Free, and Bion Tears~ (Alcon Laboratories, Inc., Fort Worth,~Texas).
Examples of phospholipid carrier formulations include those disclosed in U.S.
. . .
2o Patent Nos. 4,804,539 (Guo et al.), 4,883,658 (Holly), 4,914,088 (Glonek), 5,075,104 (Gressel et al.), 5,278,151 (Korb et al.), 5,294,607 (Glonek et al.), 5,371,108 (Korb et al.), 5,578,586 (Glonek et al.); the foregoing patents are incorporated herein by reference to the extent they disclose phospholipid compositions useful as phospholipid carriers of the present invention.
Other compounds designed to lubricate, "wet," approximate the consistency of endogenous tears, aid in natural tear build-up; or otherwise provide temporary relief of dry eye symptoms and conditions upon ocular administration the eye are known in the art. Such compounds may enhance 3o the viscosity of the composition, and include, but are not limited to:
monomeric polyols, such as, glycerol, propylene glycol, ethylene glycol;
polymeric polyols, such as, polyethylene glycol, hydroxypropylmethyl cellulose ("HPMC"), carboxy methylcellulose sodium, hydroxy propylcellulose ("HPC"), dextrans, such as, dextran 70; water soluble proteins, such as gelatin; and.
vinyl polymers, such as, polyvinyl alcohol, polyvinylpyrrolidone, povidone and carbomers, such as, carbomer 934P, carbomer 941, carbomer 940, carbomer 974P.
Other compounds may also be added to the ophthalmic compositions of the present invention to increase the viscosity or enhance the physical stability of the composition. Examples of viscosity enhancing agents include, but are not limited to: polysaccharides, such as hyaluronic acid and its salts, chondroitin sulfate and its salts, dextrans, various polymers of the cellulose family; carboxy vinyl polymers such as carbomers (e.g., carbomer 974P); and acrylic acid polymers. In general, the phospholipid carrier or artificial tears carrier compositions will exhibit a viscosity of 1 to 400 centipoises ("cps").
,5 The level of peroxy compounds in HETE derivative raw materials that rare used to prepare the pharmaceutical-formulations of the present invention may have an impact on the HETE derivative's biological activity. Although the precise relationship has not . been defiiied, it is preferable to use HETE
' derivative raw material 'supplies containing peroxy compounds at levels no .
greater than about 0.3 ppm. Methods for determining peroxy levels are known in the art (e.g., European Pharmacopoeia 1997 3rd Ed., Method 2.5.5 -Peroxide Value).
Topical ophthalmic products are typically packaged in multidose form.
z5 Preservatives are thus required to prevent microbial contamination during use. Suitable preservatives include: benzalkonium chloride, chlorobutanol, benzododecinium bromide, methyl paraben, propyl paraben, phenyiethyl alcohol, edetate disodium, sorbic acid, polyquaternium-1, or other agents known to those skilled in the art. Such preservatives are typically employed 3o at a level of from 0.001 to 1.0% wlv. Unit dose compositions of the present invention will be sterile, but typically unpreserved. Such compositions, therefore, generally will not contain preservatives.

The preferred compositions of the present invention are intended for administration to a human patient suffering from dry eye or symptoms of dry eye. Preferably, such compositions will be administered topically. In general, the doses used for the above described purposes will vary, but will be in an effective amount to eliminate or improve dry eye conditions. Generally, 1-2 drops of such compositions will be administered from once to many times per day.
A representative eye drop formulation is provided in Example 1 below.

Example 1 Ingredient Amount (% wlv) 15(S)-HETE 0.00001 - 0.0001 Rimexolone 0.01 - 0.2 Polyoxyl 40 Stearate 0.1 Boric Acid ' n p.25 Carbomer 974P . 0.45 Sodium Chloride 0.8 Disodium Edetate 0.01 Benzalkonium Chloride 0.01 NaOH/HCI q.s., pH = 7.2 0.2 Purified Water q.s. 100%

This invention has been described by reference to certain preferred embodiments; however, it should be understood that it may be embodied in ,5 ' other specific forms or variations thereof without departing from its special or essential characteristics. The embodiments described above are therefore considered to be illustrative in all respects and not restrictive, the scope of the invention being indicated by the appended claims rather than by the foregoing description.

Claims (12)

WHAT IS CLAIMED IS:
1. A composition for the treatment of dry eye and other disorders requiring the wetting of the eye comprising a pharmaceutically acceptable carrier, a pharmaceutically effective amount of an anti-inflammatory steroid and a pharmaceutically effective amount of a MUC-1 secretagogue.
2. The composition of Claim 1 wherein the anti-inflammatory steroid is selected from the group consisting of rimexolone; loteprednol; medrysone;
and hydrocortisone.
3. The composition of Claim 1 wherein the MUC-1 secretagogue is a HETE derivative selected from the group consisting of the compounds of formulas II-XIV and pharmaceutically acceptable salts, esters and amides thereof, wherein II - IV:
wherein:
Y is C=O (i.e., a carbonyl), or CH(OH) in either configuration, wherein the hydroxy group can be free or functionally modified;
V:
wherein:

Z and Z1 are H, or ZZ1 is CH2;
B5-D5, E5-G5 and T5-K5 are the same or different and are CH2CH2, CH=CH, or C.ident.C;
Y5 is C=O (i.e., a carbonyl), or CH(OH) in either configuration, wherein the hydroxy group can be free or functionally modified;
VI:
wherein:
X6 is CH2CH2CH=CH, CH2CH2C.ident.C, CH2CH2CH2CH2, CH2CH=CHCH2, CH2C.ident.CCH2, CH=CHCH2CH2, C.ident.CCH2CH2, CH2CH=C=CH, or CH=C=CHCH2;
K6-T6-6L is CH2CH2CH2, CH2CH=CH, CH2C=C, CH=CHCH2, C.ident.CCH2, or CH=C=CH;
Y6 is C=O (i.e., a carbonyl), or CH(OH) in either configuration, wherein the hydroxy group can be free or functionally modified;
VII:
wherein:
X7 is CH2CH2CH2, CH2CH=CH, CH2C.ident.C, CH=CHCH2, C.ident.CCH2, or CH=C=CH;

D7-E7 and G7-T7 are the same or different and are CH2CH2, CH=CH, or C.ident.C;
Y7 is C=O (i.e., a carbonyl), or CH(OH) in either configuration, wherein the hydroxy group can be free or functionally modified;
VIII:
wherein:
X8 is C2-C5 alkyl, alkynyl, or alkenyl, or a C3-C5 allenyl group;
J8 is H, free or functionally modified hydroxy group, halo, trihalomethyl, free or functionally modified amino group, free or functionally modified thiol group, C(O)R8, or alkyl;
R8 is H, OH, alkyl, alkoxy, amino, alkylamino, or alkoxyamino;
A8 is direct bond or C1-3 alkyl;
B8 is CH2CH2, cis- or trans-CH=CH, or C.ident.C;
Y8 is C=O (i.e., a carbonyl), or CH(OH) in either configuration, wherein the hydroxy group can be free or functionally modified;

wherein:
E9-D9 is CH2CH2CH2 or cis-CH2CH=CH; or E9 is trans-CH=CH and D9 is CH(OH) in either configuration, wherein the OH is free or functionally modified; or E9 is CH2CH2 and D9 is a direct bond;
p is 1 or 3 when E9-D9 is CH2CH2CH2 or cis-CH2CH=CH, or when E9 is trans-CH=CH and D9 is CH(OH) in either configuration, wherein the OH is free or functionally modified; or p is 0 when E9 is CH2CH2 and D9 is a direct bond;
G9-T9 is CH2CH2, CH(SR)CH2, or trans-CH=CH;
SR comprises a free or functionally modified thiol group;
n is 0, 2, or 4;
Z9 is CH3, CO2R9, CONR2R3, or CH2OR4;
R9 is H or CO2R9 forms a pharmaceutically acceptable salt or a pharmaceutically acceptable ester;
NR2R3 forms a free or functionally modified amino group;
OR4 forms a free or functionally modified hydroxy group;
Y9 is C=O (i.e., a carbonyl), or CH(OH) in either configuration, wherein the hydroxy group can be free or functionally modified;

wherein:
K10 is C2-C7 alkyl, alkenyl, or alkynyl, or a C3-C7 allenyl group;
A10 and X10 are the same or different and are a direct bond, CH2, NR11, O, or S, with the proviso that at least one of A and X is NR11, O, or S;
B10 are both H, or B10B10 together forms a double bonded O, S, or NR12, with the proviso that B10B10 is a double bonded O, S, or NR12 when A10 and X10 are the same or different and are NR11, O, or S;
NR11 and NR11 are the same or different and comprise a free or functionally modified amino group;
D10-E10 and G10-T10 are the same or different and are CH2CH2, CH=CH, or C.ident.C;
Y10 is C=O (i.e., a carbonyl), or CH(OH) in either configuration, wherein the hydroxy group can be free or functionally modified;
wherein:

A11, B11, C11 and D11 are the same or different and are C1-C5 alkyl, alkenyl, or alkynyl, or a C3-C5 allenyl group;
Y11 is C=O (i.e., a carbonyl), or CH(OH) in either configuration, wherein the hydroxy group can be free or functionally modified;
wherein:
A12, B12, C12 and D12 are the same or different and are C1-C5 alkyl, alkenyl, or alkynyl, or a C3-C5 allenyl group;
Y12 is CH(OH) or CCH3(OH) in either configuration, wherein the hydroxy group can be free or functionally modified, and X12 is CH2, CH(CH3) or C(CH3)2; or Y12 is CH2, CH(CH3) or C(CH3)2, and X12 is CH(OH) or CCH3(OH) in either configuration, wherein the hydroxy group can be free or functionally modified;
wherein:

A13, B13, C13, and D13 are the same or different and are C1-C5 alkyl, C2-C5 alkenyl, C1-C5 cyclopropyl, C2-C5 alkynyl, or a C3-C5 allenyl group;
E13 is CH(OH), where the hydroxy group is free or functionally modified;
X13 is (CH2)m or (CH2)m O, wherein m is 1-6, and Y13 is a phenyl ring optionally substituted with alkyl, halo, trihalomethyl, acyl, or a free or functionally modified hydroxy, amino, or thiol group; or X13-Y13 is (CH2)p Y21; wherein p is 0-6; and wherein:
W13 is CH2, O, S(O)q, NR18, CH2CH2, CH=CH, CH2O, CH2S(O)q, CH=N, or CH2NR18; wherein q is 0-2, and R18 is H, alkyl, or acyl;
Z13 is H, alkyl, acyl, halo, trihalomethyl, or a free or functionally modified amino, thiol, or hydroxy group; and is a single or double bond;
or X13-Y13 is cyclohexyl; and wherein:
OR14 and OR15 are the same or different and comprise a free or functionally modified hydroxy group;
G14, T14 and Z14 are the same or different and are CH2CH2, cis- or trans-CH=CH or C.ident.C;
is C.ident.C or cis-CH=CH;
one of A14, B14 is H or CH3, and the other is a free or functionally modified hydroxy group, or A14-B14 comprises a double bonded oxygen as a carbonyl, or A14-B14 is OCH2CH2O;
X14 is CR16R17(CH2)q or CR16R17(CH2)q O, with q is 0-6;
R16 and R17 are the same or different and are H or CH3;
Y14 is CH3, or a phenyl ring optionally substituted with alkyl, halo, trihalomethyl, acyl, or a free or functionally modified hydroxy, thiol, or amino group;
or X14-Y14 is (CH2)p Y20, p is 0-6, wherein:

W14 is CH2, O, S(O)m, NR21, CH2CH2 CH=CH, CH2O, CH2S(O)m, CH=N, or CH2NR21;
m is 0-2;
NR21 is NH or a functionally modified amino group;
J14 is H, alkyl, acyl, halo, trihalomethyl, or a free or functionalized hydroxy, thiol, or amino group; and is a single or double bond;
or X14-Y14 is cyclohexyl.
4. The composition of Claim 2 wherein the pharmaceutically effective amount of anti-inflammatory steroid is 0.001 to 1 %.
5. The composition of Claim 3 wherein the pharmaceutically effective amount of MUC-1 secretagogue is 0.00001 to 0.1 %.
6. The composition of Claim 1 wherein the MUC-1 secretagogue is 15(S)-HETE and the anti-inflammatory steroid is rimexolone.
7. A method of treating dry eye or other disorders requiring the wetting of the eye comprising topically administering to the eye a composition comprising a pharmaceutically acceptable carrier, a pharmaceutically effective amount of an anti-inflammatory steroid and a pharmaceutically effective amount of a MUC-1 secretagogue.
8. The method of Claim 7 wherein the anti-inflammatory steroid is selected from the group consisting of rimexolone; loteprednol; medrysone;
and hydrocortisone.
9. The method of Claim 7 wherein the MUC-1 secretagogue is a HETE
derivative selected from the group consisting of the compounds of formulas II-XIV and pharmaceutically acceptable salts, esters and amides thereof, wherein II - IV:
wherein:
Y is C=O (i.e., a carbonyl), or CH(OH) in either configuration, wherein the hydroxy group can be free or functionally modified;
wherein:
Z and Z1 are H, or ZZ1 is CH2;
B5-D5, E5-G5 and T5-K5 are the same or different and are CH2CH2, CH=CH, or C.ident.C;
Y5 is C=O (i.e., a carbonyl), or CH(OH) in either configuration, wherein the hydroxy group can be free or functionally modified;

wherein:
X6 is CH2CH2CH=CH, CH2CH2C.ident.C, CH2CH2CH2CH2, CH2CH=CHCH2, CH2C.ident.CCH2, CH=CHCH2CH2, C.ident.CCH2CH2, CH2CH=C=CH, or CH=C=CHCH2;
K6-T6-L6 is CH2CH2CH2, CH2CH=CH, CH2C.ident.C, CH=CHCH2, C.ident.CCH2, or CH=C=CH;
Y6 is C=O (i.e., a carbonyl), or CH(OH) in either configuration, wherein the hydroxy group can be free or functionally modified;
wherein:
X7 is CH2CH2CH2, CH2CH=CH, CH2C.ident.C, CH=CHCH2, C.ident.CCH2, or CH=C=CH;
D7-E7 and G7-T7 are the same or different and are CH2CH2, CH=CH, or C.ident.C;
Y7 is C=O (i.e., a carbonyl), or CH(OH) in either configuration, wherein the hydroxy group can be free or functionally modified;

wherein:
X8 is C2-C5 alkyl, alkynyl, or alkenyl, or a C3-C5 allenyl group;
J8 is H, free or functionally modified hydroxy group, halo, trihalomethyl, free or functionally modified amino group, free or functionally modified thiol group, C(O)R8, or alkyl;
R8 is H, OH, alkyl, alkoxy, amino, alkylamino, or alkoxyamino;
A8 is direct bond or C1-3 alkyl;
B8 is CH2CH2, cis- or trans-CH=CH, or C.ident.C;
Y8 is C=O (i.e., a carbonyl), or CH(OH) in either configuration, wherein the hydroxy group can be free or functionally modified;
wherein:
E9-D9 is CH2CH2CH2 or cis-CH2CH=CH; or E9 is trans-CH=CH and D9 is CH(OH) in either configuration, wherein the OH is free or functionally modified; or E9 is CH2CH2 and D9 is a direct bond;

p is 1 or 3 when E9-D9 is CH2CH2CH2 or cis-CH2CH=CH, or when E9 is traps-CH=CH and D9 is CH(OH) in either configuration, wherein the OH is free or functionally modified; or p is 0 when E9 is CH2CH2 and D9 is a direct bond;
G9-T9 is CH2CH2, CH(SR)CH2, or traps-CH=CH;
SR comprises a free or functionally modified thiol group;
n is 0, 2, or 4;
Z9 is CH3, CO2R9, CONR2R3, or CH2OR4;
R9 is H or CO2R9 forms a pharmaceutically acceptable salt or a pharmaceutically acceptable ester;
NR2R3 forms a free or functionally modified amino group;
OR4 forms a free or functionally modified hydroxy group;
Y9 is C=O (i.e., a carbonyl), or CH(OH) in either configuration, wherein the hydroxy group can be free or functionally modified;
X:
wherein:
K10 is C2-C7 alkyl, alkenyl, or alkynyl, or a C3-C7 allenyl group;

A10 and X10 are the same or different and are a direct bond, CH2, NR11, O, or S, with the proviso that at least one of A and X is NR11, O, or S;
B10 are both H, or B10B10 together forms a double bonded O, S, or NR12, with the proviso that B10B10 is a double bonded O, S, or NR12 when A10 and X10 are the same or different and are NR11, O, or S;
NR11 and NR12 are the same or different and comprise a free or functionally modified amino group;
D10-E10 and G10-T10 are the same or different and are CH2CH2, CH=CH, or C.ident.C;
Y10 is C=O (i.e., a carbonyl), or CH(OH) in either configuration, wherein the hydroxy group can be free or functionally modified;
XI:

wherein:
A11, B11, C11 and D11 are the same or different and are C1-C5 alkyl, alkenyl, or alkynyl, or a C3-C5 allenyl group;
Y11 is C=O (i.e., a carbonyl), or CH(OH) in either configuration, wherein the hydroxy group can be free or functionally modified;

XII:
wherein:
A12, B12, C12 and D12 are the same or different and are C1-C5 alkyl, alkenyl, or alkynyl, or a C3-C5 allenyl group;

Y12 is CH(OH) or CCH3(OH) in either configuration, wherein the hydroxy group can be free or functionally modified, and X12 is CH2, CH(CH3) or C(CH3)2; or Y12 is CH2, CH(CH3) or C(CH3)2, and X12 is CH(OH) or CCH3(OH) in either configuration, wherein the hydroxy group can be free or functionally modified;
XIII:
wherein:
A13, B13, C13 and D13 are the same or different and are C1-C5 alkyl, C2-C5 alkenyl, C1-C5 cyclopropyl, C2-C5 alkynyl, or a C3-C5 allenyl group;
E13 is CH(OH), where the hydroxy group is free or functionally modified;

X13 is (CH2)m or (CH2)mO, wherein m is 1-6, and Y13 is a phenyl ring optionally substituted with alkyl, halo, trihalomethyl, acyl, or a free or functionally modified hydroxy, amino, or thiol group; or X13-Y13 is (CH2)pY21; wherein p is 0-6; and wherein:
W13 is CH2, O, S(O)q, NR18, CH2CH2, CH=CH, CH20, CH2S(O)q, CH=N, or CH2NR18; wherein q is 0-2, and R18 is H, alkyl, or acyl;

Z13 is H, alkyl, acyl, halo, trihalomethyl, or a free or functionally modified amino, thiol, or hydroxy group; and -- is a single or double bond;
or X13-Y13 is cyclohexyl; and XIV:
wherein:
OR~4 and OR'5 are the same or different and comprise a free or functionally modified hydroxy group;

G14, T14 and Z14 are the same or different and are CH2CH2, cis- or trans-CH=CH or C.ident.C;
is C.ident.C or cis-CH=CH;

one of A14, B14 is H or CH3, and the other is a free or functionally modified hydroxy group, or A14-B14 comprises a double bonded oxygen as a carbonyl, or A14-B14 is OCH2CH2O;

X14 is CR16R17(CH2)q or CR16R17(CH2)q O, with q is 0-6;
R16 and R17 are the same or different and are H or CH3;
Y14 is CH3, or a phenyl ring optionally substituted with alkyl, halo, trihalomethyl, acyl, or a free or functionally modified hydroxy, thiol, or amino group;
or X14-Y14 is (CH2)p Y20, p is 0-6, wherein:
W14 is CH2, O, S(O)m, NR21, CH2CH2, CH=CH, CH2O, CH2S(O)m, CH=N, or CH2NR21;
m is 0-2;

NR21 is NH or a functionally modified amino group;

J14 is H, alkyl, acyl, halo, trihalomethyl, or a free or functionalized hydroxy, thiol, or amino group; and -- is a single or double bond;

or X14-Y14 is cyclohexyl.
10. The method of Claim 8 wherein the pharmaceutically effective amount of ocular surface selective steroid is 0.001 to 1 %.
11. The method of Claim 9 wherein the pharmaceutically effective amount of MUC-1 secretagogue is 0.00001 to 0.1 %.
12. The method of Claim 7 wherein the MUC-1 secretagogue is 15(S)-HETE and the anti-inflammatory steroid is rimexolone.
CA002462272A 2001-10-11 2002-09-26 Methods for treating dry eye by a combination of an antiinflammatory steroid and a muc-1 secretagogue Abandoned CA2462272A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32860801P 2001-10-11 2001-10-11
US60/328,608 2001-10-11
PCT/US2002/030681 WO2003030893A1 (en) 2001-10-11 2002-09-26 Methods for treating dry eye by a combination of an antiinflammatory steroid and a muc-1 secretagogue

Publications (1)

Publication Number Publication Date
CA2462272A1 true CA2462272A1 (en) 2003-04-17

Family

ID=23281647

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002462272A Abandoned CA2462272A1 (en) 2001-10-11 2002-09-26 Methods for treating dry eye by a combination of an antiinflammatory steroid and a muc-1 secretagogue

Country Status (11)

Country Link
US (2) US20030109509A1 (en)
EP (1) EP1438037A1 (en)
JP (1) JP2005505592A (en)
KR (1) KR20050030884A (en)
CN (1) CN1564683A (en)
BR (1) BR0213179A (en)
CA (1) CA2462272A1 (en)
MX (1) MXPA04003299A (en)
PL (1) PL369960A1 (en)
WO (1) WO2003030893A1 (en)
ZA (1) ZA200402356B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070004750A (en) * 2004-03-25 2007-01-09 보오슈 앤드 롬 인코포레이팃드 Use of loteprednol etabonate for the treatment of dry eye
US7189697B2 (en) * 2004-04-13 2007-03-13 Trustees Of Tufts College Compositions and uses of a galectin for treatment of dry eye syndrome
US20070014833A1 (en) * 2005-03-30 2007-01-18 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators
US20060292099A1 (en) * 2005-05-25 2006-12-28 Michael Milburn Treatment of eye disorders with sirtuin modulators
WO2007032997A1 (en) * 2005-09-13 2007-03-22 Bausch & Lomb Incorporated Ophthalmic formulation containing loteprednol etabonate for treatment of dry eye
US7687484B2 (en) * 2006-05-25 2010-03-30 Bodor Nicholas S Transporter enhanced corticosteroid activity
US7691811B2 (en) * 2006-05-25 2010-04-06 Bodor Nicholas S Transporter-enhanced corticosteroid activity and methods and compositions for treating dry eye
US20080161275A1 (en) * 2006-12-05 2008-07-03 Resolvyx Pharmaceuticals, Inc. Compositions and methods for the treatment of inflammatory disease
ATE541841T1 (en) 2007-11-15 2012-02-15 Boehringer Ingelheim Int INHIBITORS OF REPLICATION OF THE HUMAN IMMUNODEFICIENCY VIRUS
EP2220046B1 (en) 2007-11-16 2014-06-18 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
US9289494B2 (en) 2013-11-20 2016-03-22 RestorTears, LLC Method of treating ocular disorders with compounds found in Harderian gland secretions
JP2019524892A (en) * 2016-08-19 2019-09-05 アクリビスタ エルエルシーAkrivista,Llc Methods for diagnosing and treating dry eye syndrome and compositions for treating human eyes
JP7311160B2 (en) 2017-08-18 2023-07-19 アクリビスタ エルエルシー Methods for diagnosing and treating dry eye syndrome and compositions for treating the human eye

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4131651A (en) * 1977-10-25 1978-12-26 Barnes-Hind Pharmaceuticals, Inc. Treatment of dry eye
US4409205A (en) * 1979-03-05 1983-10-11 Cooper Laboratories, Inc. Ophthalmic solution
US4370325A (en) * 1979-03-30 1983-01-25 Dermik Laboratories Pharmaceutical compositions and method of treatment
US4633392A (en) * 1982-04-05 1986-12-30 Texas Instruments Incorporated Self-configuring digital processor system with logical arbiter
US4868154A (en) * 1986-02-19 1989-09-19 Eye Research Institute Of Retina Foundation Stimulation of tear secretion with melanocyte stimulating hormones
US4753945A (en) * 1986-02-19 1988-06-28 Eye Research Institute Of Retina Foundation Stimulation of tear secretion with phosphodiesterase inhibitors
US4883658A (en) * 1986-04-28 1989-11-28 Holly Frank J Ophthalmic solution for treatment of dry-eye syndrome
US4744980A (en) * 1986-04-28 1988-05-17 Holly Frank J Ophthalmic solution for treatment of dry eye syndrome
US4804539A (en) * 1986-07-28 1989-02-14 Liposome Technology, Inc. Ophthalmic liposomes
US4818537A (en) * 1986-10-21 1989-04-04 Liposome Technology, Inc. Liposome composition for treating dry eye
US4966773A (en) * 1986-11-25 1990-10-30 Alcon Laboratories, Inc. Topical ophthalmic compositions containing microfine retinoid particles
US5278151A (en) * 1987-04-02 1994-01-11 Ocular Research Of Boston, Inc. Dry eye treatment solution
US4914088A (en) * 1987-04-02 1990-04-03 Thomas Glonek Dry eye treatment solution and method
US5075104A (en) * 1989-03-31 1991-12-24 Alcon Laboratories, Inc. Ophthalmic carboxy vinyl polymer gel for dry eye syndrome
US5174988A (en) * 1989-07-27 1992-12-29 Scientific Development & Research, Inc. Phospholipid delivery system
US5041434A (en) * 1991-08-17 1991-08-20 Virginia Lubkin Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application
DE69115990T2 (en) * 1990-05-29 1996-05-30 Ocular Res Of Bonton Inc Composition for the treatment of dry eye diseases
ZA912797B (en) * 1990-05-29 1992-12-30 Boston Ocular Res Dry eye treatment process and solution
JPH0727504B2 (en) * 1990-12-10 1995-03-29 インターナショナル・ビジネス・マシーンズ・コーポレイション System for defining network configuration, method for generating configuration parameters for network, and system for configuring network
AU1645092A (en) * 1991-03-18 1992-10-21 Echelon Corporation Binder interface structure
ZA927277B (en) * 1991-10-02 1993-05-19 Boston Ocular Res Dry eye treatment process and solution.
CA2133966C (en) * 1992-04-21 1997-09-09 David A. Sullivan Ocular androgen therapy in sjogren's syndrome
US6107289A (en) * 1992-04-21 2000-08-22 The Schepens Eye Research Institute, Inc. Ocular therapy in keratoconjunctivitis sicca using topically applied androgens or TGF-β
US5688765A (en) * 1992-04-21 1997-11-18 The Schepens Eye Research Institute, Inc. Ocular therapy in Sjogren's syndrome using topically applied androgensor TGF-β
US5958912A (en) * 1992-04-21 1999-09-28 The Schepens Eye Research Institute, Inc. Ocular therapy in keratoconjunctivitis sicca using topically applied androgens of TGF-β
US5805897A (en) * 1992-07-31 1998-09-08 International Business Machines Corporation System and method for remote software configuration and distribution
US5290572A (en) * 1992-08-06 1994-03-01 Deo Corporation Opthalmic composition for treating dry eye
WO1994004155A1 (en) * 1992-08-19 1994-03-03 Health Resource Institute, Ltd. Dehydroepiandrosterone therapy for the treatment of eye disorders
US5455265A (en) * 1993-02-11 1995-10-03 Allergan, Inc. Method of treatment with compounds having selective agonist-like activity on RXR retinoid receptors
US5845090A (en) * 1994-02-14 1998-12-01 Platinium Technology, Inc. System for software distribution in a digital computer network
US5500802A (en) * 1994-05-31 1996-03-19 Morris; James M. System and method for creating configurators using templates
JP3611610B2 (en) * 1994-11-18 2005-01-19 富士通株式会社 Automatic generation method of device connection definition in data independent computer system
US5872928A (en) * 1995-02-24 1999-02-16 Cabletron Systems, Inc. Method and apparatus for defining and enforcing policies for configuration management in communications networks
US5894571A (en) * 1995-08-14 1999-04-13 Dell U.S.A., L.P. Process for configuring software in a build-to-order computer system
US5696166A (en) * 1995-10-31 1997-12-09 Yanni; John M. Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders
WO1997020578A1 (en) * 1995-12-04 1997-06-12 University Of Miami Non-preserved topical corticosteroid for treatment of dry eye, filamentary keratitis, and delayed tear clearance
US6035105A (en) * 1996-01-02 2000-03-07 Cisco Technology, Inc. Multiple VLAN architecture system
US5900407A (en) * 1997-02-06 1999-05-04 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with uridine triphosphates and related compounds
US5724509A (en) * 1996-04-22 1998-03-03 Motorola, Inc. Method and apparatus for synchronizing implementation of configuration information in a communication system
US6061332A (en) * 1996-06-25 2000-05-09 Mci Communications Corporation System and method for the automated configuration of network elements in a telecommunications network
US5758071A (en) * 1996-07-12 1998-05-26 Electronic Data Systems Corporation Method and system for tracking the configuration of a computer coupled to a computer network
US5875306A (en) * 1996-10-01 1999-02-23 International Business Machines Corporation Reconfiguring computer resources in a distributed computer enterprise environment
US6009274A (en) * 1996-12-13 1999-12-28 3Com Corporation Method and apparatus for automatically updating software components on end systems over a network
US5841972A (en) * 1997-01-03 1998-11-24 Ncr Corporation System using displayed configuration utility on monitor including list of target nodes, for administering interconnected nodes of computer network
US5800807A (en) * 1997-01-29 1998-09-01 Bausch & Lomb Incorporated Ophthalmic compositions including glycerin and propylene glycol
US6243815B1 (en) * 1997-04-25 2001-06-05 Anand K. Antur Method and apparatus for reconfiguring and managing firewalls and security devices
US5951680A (en) * 1997-06-24 1999-09-14 International Business Machines Corporation Configurator object
US6247128B1 (en) * 1997-07-22 2001-06-12 Compaq Computer Corporation Computer manufacturing with smart configuration methods
US5995757A (en) * 1997-08-29 1999-11-30 Dell Usa, L.P. Software installation and testing for a build-to order computer system
US6154835A (en) * 1997-10-01 2000-11-28 Micron Electronics, Inc. Method for automatically configuring and formatting a computer system and installing software
US6263387B1 (en) * 1997-10-01 2001-07-17 Micron Electronics, Inc. System for automatically configuring a server after hot add of a device
US6041347A (en) * 1997-10-24 2000-03-21 Unified Access Communications Computer system and computer-implemented process for simultaneous configuration and monitoring of a computer network
US6233609B1 (en) * 1997-10-31 2001-05-15 Selectica, Inc Method and apparatus for remote interaction with and configuration of a wan-based knowledge base
US6064982A (en) * 1997-11-12 2000-05-16 Netscape Communication Corporation Smart configurator
US6295556B1 (en) * 1997-11-18 2001-09-25 Microsoft Corporation Method and system for configuring computers to connect to networks using network connection objects
US6317815B1 (en) * 1997-12-30 2001-11-13 Emc Corporation Method and apparatus for formatting data in a storage device
US6202070B1 (en) * 1997-12-31 2001-03-13 Compaq Computer Corporation Computer manufacturing system architecture with enhanced software distribution functions
US6182275B1 (en) * 1998-01-26 2001-01-30 Dell Usa, L.P. Generation of a compatible order for a computer system
US6236901B1 (en) * 1998-03-31 2001-05-22 Dell Usa, L.P. Manufacturing system and method for assembly of computer systems in a build-to-order environment
US6092189A (en) * 1998-04-30 2000-07-18 Compaq Computer Corporation Channel configuration program server architecture
US6173319B1 (en) * 1998-05-08 2001-01-09 Attachmate Corporation Using a systems network architecture logical unit activation request unit as a dynamic configuration definition in a gateway
US6263382B1 (en) * 1998-07-29 2001-07-17 Compaq Computer Corporation Sizer for interactive computer system configuration
US6066182A (en) * 1998-11-05 2000-05-23 Platinum Technology Ip, Inc. Method and apparatus for operating system personalization during installation
US6347331B1 (en) * 1999-04-26 2002-02-12 International Business Machines Corporation Method and apparatus to update a windows registry from a hetrogeneous server
BR0015392A (en) * 1999-11-09 2002-06-25 Alcon Inc Lipoxin a4 and its analogs for the treatment of dry eye
TR200201251T2 (en) * 1999-11-09 2002-11-21 Alcon, Inc. Omega chain modified 15-hydroxyiecosetetraenoic acid derivatives and their use methods for improving eye dryness
DE60010503T2 (en) * 1999-11-09 2004-09-23 Alcon, Inc. TRI-HETEROATOM-SUBSTITUTED AND TWO CARBON HOMOLOGE OF 15-HETE AND METHOD FOR USE

Also Published As

Publication number Publication date
US20060069075A1 (en) 2006-03-30
CN1564683A (en) 2005-01-12
BR0213179A (en) 2004-09-14
PL369960A1 (en) 2005-05-02
EP1438037A1 (en) 2004-07-21
MXPA04003299A (en) 2004-07-23
WO2003030893A1 (en) 2003-04-17
ZA200402356B (en) 2005-03-29
JP2005505592A (en) 2005-02-24
KR20050030884A (en) 2005-03-31
US20030109509A1 (en) 2003-06-12

Similar Documents

Publication Publication Date Title
US20060069075A1 (en) Methods for treating dry eye
US6645978B1 (en) Lipoxin A4 and its analogs for the treatment of dry eye
US6740674B2 (en) Use of proteasome inhibitors to treat dry eye disorders
AU2002308760A1 (en) Use of proteasome inhibitors to treat dry eye disorders
EP1744736A1 (en) Method of treating dry eye disorders and uveitis
ES2208441T3 (en) COMPOUNDS RELATED TO 15-HYDROXIEICOSATETRAENOIC ACID AND METHODS OF USE.
US20030109508A1 (en) Methods for treating dry eye
AU775290B2 (en) Omega chain modified 15-hydroxyeicosatetraenoic acid derivatives and methods of their use for the treatment of dry eye
ES2215740T3 (en) HOMOLOGOS OF 15-HETE WITH REPLACEMENT 3-HETEROATOMICA AND TWO CARBONS, AND METHOD OF USE.
US20030109488A1 (en) Methods for treating dry eye
ES2239621T3 (en) BENCENOID DERIVATIVES OF 15-HYDROXIEICOSATETRAENOIC ACID AND METHODS FOR USE IN THE TREATMENT OF DRY EYE DISORDERS.
US6458854B2 (en) Phospholipids of hydroxyeicosatetraenoic acid-like derivatives and methods of use
AU2002334697A1 (en) Methods for treating dry eye by a combination of an antiinflammatory steroid and a MUC-1 secretagogue
US7112588B2 (en) Use of proteasome inhibitors to treat dry eye disorders
US7060728B2 (en) 11,12-oxidoarachidonic acid derivatives and methods of their use in treating dry eye disorders
EP1393277B1 (en) USE OF NF-Kappa-B INHIBITORS TO TREAT DRY EYE DISORDERS
US20040209888A1 (en) Methods of treating dry eye disorders

Legal Events

Date Code Title Description
FZDE Discontinued